Peptides
Semaglutide
Semaglutide is a GLP-1 receptor agonist widely studied in metabolic research. Below, we compare vendors currently stocking research-grade Semaglutide — not just a single sales page.
Semaglutide is a GLP-1 receptor agonist widely studied in metabolic research. Below, we compare vendors currently stocking research-grade Semaglutide — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 American PeptidesBest Value |
From $60.00 | Third-party COA | Buy Here → | |
 Amino Vault |
$68.85 (AminoGLP-1 SEMA) | Third-party COA | Buy Here → | |
 Purity Peptides |
$89.99 – $119.99 | Third-party COA | Buy Here → |
Semaglutide is a GLP-1 receptor agonist and one of the most clinically established compounds in this category, holding FDA approval under three brand names — Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management.
Research-grade Semaglutide is typically supplied as a lyophilized powder in sealed vials, commonly at 2mg to 10mg strengths, intended for laboratory research use; the FDA-approved pharmaceutical products are separate, prescription-only formulations manufactured by Novo Nordisk.
Semaglutide mimics the naturally occurring incretin hormone GLP-1, slowing gastric emptying, increasing insulin secretion in response to meals, and acting on appetite-regulating centers in the hypothalamus — mechanisms documented extensively across its clinical trial program.
Semaglutide's original approval was for type 2 diabetes management, supported by a large body of Phase 3 trial data (the SUSTAIN program) demonstrating improved blood glucose control.
Subsequent trials (the STEP program) established Semaglutide's efficacy for chronic weight management at higher doses, leading to its approval as Wegovy and making it one of the most-studied compounds in current obesity pharmacology.
As an FDA-approved medication, Semaglutide's side-effect profile is well documented in its prescribing information, most commonly gastrointestinal effects (nausea, vomiting, diarrhea, constipation), along with rare but serious risks discussed in its labeling (such as pancreatitis and gallbladder disease). Research-grade material sourced outside the regulated pharmacy supply chain has not undergone the same quality controls and carries additional, unverified risk.
The FDA-approved clinical dosing follows a titration schedule specific to each branded product and indication, detailed in the respective prescribing information for Ozempic, Wegovy, and Rybelsus — this reflects the approved clinical protocol, not a recommendation for use of unregulated research material.
Compound X does not sell Semaglutide directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
Semaglutide's extensive clinical trial data (SUSTAIN and STEP programs) and prescribing information are available via the FDA and indexed on PubMed under "Semaglutide GLP-1 clinical trial."
New guides, vendor comparisons and compound breakdowns every week.